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Abstract ATP is a gliotransmitter released from astrocytes.
Extracellularly, ATP is metabolized by a series of enzymes,
including ecto-5′-nucleotidase (eN; also known as CD73)
which is encoded by the gene 5NTE and functions to form
adenosine (ADO) from adenosine monophosphate (AMP).
Under ischemic conditions, ADO levels in brain increase up
to 100-fold. We used astrocytes cultured from 5NTE+/+ or
5NTE −/− mice to evaluate the role of eN expressed by astro-
cytes in the production of ADO and inosine (INO) in response
to glucose deprivation (GD) or oxygen-glucose deprivation
(OGD). We also used co-cultures of these astrocytes with
wild-type neurons to evaluate the role of eN expressed by
astrocytes in the production of ADO and INO in response to
GD, OGD, or N-methyl-D-aspartate (NMDA) treatment. As
expected, astrocytes from 5NTE+/+ mice produced adenosine
from AMP; the eN inhibitor α,β-methylene ADP (AOPCP)
decreased ADO formation. In contrast, little ADOwas formed
by astrocytes from 5NTE−/− mice and AOPCP had no signif-
icant effect. GD and OGD treatment of 5NTE+/+ astrocytes
and 5NTE+/+ astrocyte-neuron co-cultures produced extracel-
lular ADO levels that were inhibited by AOPCP. In contrast,
these conditions did not evoke ADO production in cultures
containing 5NTE−/− astrocytes. NMDA treatment produced
similar increases in ADO in both 5NTE+/+ and 5NTE−/−
astrocyte-neuron co-cultures; dipyridamole (DPR) but not
AOPCP inhibited ADO production. These results indicate that
eN is prominent in the formation of ADO from astrocytes but
in astrocyte-neuron co-cultures, other enzymes or pathways
contribute to rising ADO levels in ischemia-like conditions.
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Introduction
ATP is the energy molecule of cells. ATP levels fall during
conditions characterized by reduced oxygen and glucose
availability and/or increased cellular energy demand.
Adenosine (ADO) is a metabolite of ATP and increased
metabolism of intracellular ATP can directly increase intracel-
lular ADO levels, which can be released from cells through
equilibrative nucleoside transport proteins 1 and/or 2 (ENT1,
ENT2) [1–3]. This ADO activates specific receptors of the G
protein-coupled receptor family, principally A1 and A2A re-
ceptors [4].
In addition to its role in energy requiring intracellular
processes, ATP is also a signaling molecule and is released
from diverse cell types, including astrocytes and neurons, in
response to stimuli such as increases in cytosolic calcium
levels [3, 5]. Extracellular ATP can access its receptors, broad-
ly classified as P2X, ion channel receptors, and P2Y, G
protein-coupled receptors [4, 6]. Also in the extracellular
environment, ATP can be acted upon by a cascade of hydro-
lase enzymes to dephosphorylate ATP to ADO [7]. The final
enzyme in this cascade is ecto-5′-nucleotidase (eN); the pro-
tein corresponding to this enzyme is also known as CD73
whereas the gene is known as 5NTE [7].
ADO levels in the brain are under control of ENT1 and/or
ENT2, which facilitate the movement of nucleosides, includ-
ing ADO and inosine (INO), across cell membranes. Both
ENT1 and ENT2 transporters can be inhibited pharmacolog-
ically by dipyridamole (DPR) or dilazep at micromolar con-
centrations [1]. ADO levels are also regulated by enzymes that
produce or metabolize ADO, including adenosine kinase,
adenosine deaminase, and 5′-nucleotidases. eN is primarily
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expressed in astrocytes [8] but has also been localized to
synaptic membranes [9] and is an important enzyme for the
extracellular formation of ADO [7].
Previous studies with cultured rat cortical astrocytes and
neurons reported that, during ischemia-like conditions, astro-
cytes released adenine nucleotides that were metabolized ex-
tracellularly to ADO whereas neurons released ADO directly
via ENT1/ENT2 [3, 10]. Using mouse hippocampal slices,
neuronal overexpression of ENT1 was found to reduce extra-
cellular ADO levels in basal and ischemia-like conditions,
indicating that the extracellular pathway for ADO formation
predominated in normoxic, hypoxic, and oxygen-glucose dep-
rivation [11]. However, using hippocampal slices from
5NTE−/− mice, a role for eN could not be demonstrated for
ADO formation in response to hypoxia or oxygen-glucose
deprivation [12].
The present studies were performed to examine the role of
eN on astrocytes for ADO formation evoked by experimental
conditions that simulate ischemia, such as glucose deprivation
(GD), oxygen-glucose deprivation (OGD), and activation of
N-methyl-D-aspartate (NMDA) glutamate receptors. We used
cultures of astrocytes from 5NTE+/+ and 5NTE−/−mice as well
as co-cultures of wild type neurons with 5NTE+/+ or 5NTE−/−
astrocytes. In addition to ADO, we also measured its metab-
olite INO. The pharmacological tools DPR, dilazep, and α,β-
methylene ADP (AOPCP), an inhibitor of eN, were used to
assess the roles of ENT1/ENT2 and eN, respectively, in reg-
ulating extracellular levels of ADO and INO.
Experimental methods
Materials
Neurobasal media, Dulbecco’s modified Eagle medium-F12
(DMEM-F12), B-27 supplement, fetal bovine serum (FBS), L-
glutamine, and antibiotic/antimycotic (penicillin, streptomy-
cin, amphotericin B) were purchased from Invitrogen
(Burlington, Ontario, Canada). [3H] Adenine was purchased
from Perkin Elmer (Boston, MA). [14C] AMP was purchased
from Amersham Biosciences (Baie d’Urfe, Quebec, Canada).
Silica gel-coated glass plates were obtained from Fisher
Scientific (Whitby, Ontario, Canada). DPR, dilazep, AOPCP,
NMDA, glutamic acid, 2-deoxyglucose (2DG), and adenosine
monophosphate (AMP) were purchased from Sigma-Aldrich
Canada (Oakville, ON). C57Bl6 mice lacking eN expression
(5NTE−/−) mice were obtained fromDr. Linda Thompson [13]
and bred locally.
Cell culture
Primary astrocytes were cultured from cerebral cortices from
5NTE+/+ or 5NTE−/−mice (0–3 days). Cortices were triturated
several times, centrifuged at 200×g for 5 min, then resuspend-
ed and plated on 150-cm2 flasks. After 5–7 days in vitro
(DIV), flasks were shaken at 300 rpm in an orbital shaker at
37 °C for 14 h to remove microglia and then plated on 12-well
culture plates. Astrocytes were fed every 3 days with DMEM-
F12 supplemented with 10 % FBS, 100 units/ml of penicillin,
100 μg/ml of streptomycin, and 0.25 μg/ml of amphotericin B
and used at 14–21 DIV.
For primary neuron cultures, the cerebral cortices from
gestational day 17 CD1 mice were isolated and triturated.
Cells were incubated for 1 h at 37 °C in 150-cm2 flasks to
allow any contaminating astrocytes to adhere. Neurons were
counted and plated (30,000 per well) on top of a semi-
confluent (70 %) layer of astrocytes (DIV 7–12) in 12-well
plates. For 24 h prior to addition of neurons, astrocytes were
pre-conditioned to Neurobasal media containing 2 % B-27
supplement, 100 units/ml of penicillin, 100 μg/ml of strepto-
mycin, 0.25 μg/ml of amphotericin B, 500 μM L-glutamine,
and 25 μMglutamic acid. After 4 days in vitro (DIV), half the
media was replaced with fresh media without glutamic acid.
Co-cultures were used in experiments 10 days following
addition of neurons.
All procedures with animals were in accordance with ani-
mal care guidelines set by the Canadian Council on Animal
Care approved by the University of Manitoba Animal
Protocol Management and Review Committee.
Ecto-5′-nucleotidase (eN) Assay
eN enzyme activity was assessed in 5NTE+/+ and 5NTE−/−
tissue samples and astrocyte cultures. To determine activity in
brain tissue, cerebral cortices from 5NTE+/+ and 5NTE−/−mice
were homogenized in 0.32 M sucrose with glass/Teflon ho-
mogenizer. The homogenate was centrifuged at 1,000×g for
10 min and the pellet was washed twice in 0.32 M sucrose
solution. The supernatants were collected at the end of each
wash step, up to three times. The pooled supernatant was
centrifuged at 20,000×g for 45 min at 4 °C. Following this,
the supernatant was discarded and the pellet was resuspended
in 4-2-hydroxyethyl-1-piperazineethanesulfonic acid
(HEPES) buffer (110 mM NaCl, 25 mM glucose, 68.3 mM
sucrose, 5.3 mM KCl, 1.8 mM CaCl2, 1.0 mM MgSO4, and
20 mMHEPES; pH 7.4) and then assayed for protein content.
Samples were stored at −80 °C.
Tissue eN assay was performed with total reaction volume
of 0.3 ml. This mixture consisted of 0.1 ml cortex membrane
protein, prepared to final concentrations of 10 μg/ml, 0.1 ml
[14C] AMP (300 μM), and 0.1 ml of buffer with or without
AOPCP (50 μM). After 10-min incubation, samples were
centrifuged for 2 min to collect supernatant to assess [14C]
purine content by TLC and scintillation spectroscopy, as pre-
viously described [10].
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For cell cultures, primary astrocytes were grown on 12-
well plates. The medium was aspirated from wells and cells
were gently washed twice with buffer. Cells were then incu-
bated with 30 μM DPR in buffer for 15 min at room temper-
ature. Following this, 1.85 kBq [14C] AMP (10 μM) contain-
ing 30 μMDPRwith or without 50 μMAOPCP was added to
cells for 10min at room temperature. DPRwas included in the
assays to minimize cellular uptake of any [14C] ADO formed.
After incubation, the extracellular medium was extracted and
assayed for [14C] purines by TLC. Cells were lysed with
1.0 M NaOH and measured for intracellular [14C] purines
and protein content.
Nucleoside release assays
All experiments with astrocytes or co-cultures were performed
with physiological buffer that contained a final concentration
of 25 mM HEPES, 2.9 mM KCl, 1.2 mM MgCl2, 4.9 mM
KCl, 1.4 mM KH2PO4, 1 mM CaCl2, 118 mM NaCl, and
11 mM glucose, at pH 7.4, and an osmolarity of 300±
10 mOsm. Cells were washed twice with buffer (37 °C) and
then incubated with 13.7 kBq [3H] adenine for 30 min at
37 °C. The [3H] adenine is taken up by cells and is metabo-
lized to [3H] adenine nucleotides [10]. To assay nucleoside
release in response to ischemia-like conditions, cells were
washed to remove extracellular [3H] adenine then treated with
buffer (control), glucose deprivation (GD), or oxygen-glucose
deprivation (OGD) in the absence or presence of AOPCP
(50 μM), to inhibit eN, or DPR (30 μM), to inhibit ENT1
and ENT2. In some experiments, dilazep (100 μM) was used
in place of DPR. For GD, cells were treated for 30 min at
37 °C with buffer in which glucose was replaced with 2DG
(10 mM) to inhibit glycolysis. For OGD treatment, cells were
treated with 2DG containing buffer and were placed in a
humidified chamber containing 95 % N2 and 5 % CO2 for
1 h at 37 °C. Oxygen content in the chamber was monitored
with a ProOx 110 controller and maintained at 2 %.
To assay nucleoside release in response to glutamate re-
ceptor activation, cells were washed to remove extracellular
[3H] adenine then treated with buffer (control), NMDA
(100 μM), DPR (30 μM), or AOPCP (50 μM), separately or
in combination, for 30 min at 37 °C. After incubation, the
supernatants were collected and 0.4 ml was quantified for
extracellular [3H] purines by TLC and scintillation spectrom-
etry. Cells were dissolved in 0.35 ml 1 M NaOH overnight at
37 °C; 0.2 ml of the cell lysate was counted for intracellular
radioactivity and 0.1 ml for protein content.
Statistical analysis
All data are reported as means±SEM. Data were obtained
from a minimum of three independent culture preparations;
reported n values are the total number of replicates. Statistical
significance between two means was determined by unpaired
Student’s t test; statistical significance between three or more
means was determined by one-way ANOVA with Tukey’s
post hoc tests.
Results
AOPCP inhibits ADO production from AMP in cortical
membranes and cortical astrocytes from 5NTE+/+ but not
5NTE−/− mice
For tissue eN assays, membrane proteins from 5NTE+/+ and
5NTE−/− cerebral cortex was incubated with AMP. As shown
in Fig. 1a, ADO was the most abundant purine formed and 6-
fold more ADO was formed with 5NTE+/+ tissue than with
5NTE−/− tissue. AOPCP significantly inhibited the formation
of ADO in 5NTE+/+ tissue, but not in 5NTE−/− tissue. In the
presence of AOPCP, ADO formation was not significantly
different between 5NTE+/+ and 5NTE−/− samples.
The activity of membrane-bound eN was assayed in cul-
tures of 5NTE+/+ and 5NTE−/− astrocytes (Fig. 1b). Similar to
the results with cortical membranes, 5NTE+/+ astrocytes pro-
duced 8-fold more ADO from AMP than 5NTE−/− astrocytes.
While AOPCP significantly inhibited ADO formation by
5NTE+/+ astrocytes, it had no significant effect on the low
levels of ADO formed by 5NTE−/− astrocytes.
In ischemia-like conditions, 5NTE+/+ astrocytes produce more
ADO but similar INO compared to 5NTE−/− astrocytes
Primary cultured astrocytes from 5NTE+/+ and 5NTE−/− mice
were compared to assess ADO and INO release under phys-
iological buffer (control), GD, or OGD conditions. Compared
to 5NTE+/+ astrocytes, the 5NTE−/− cells produced significant-
ly less ADO in all three conditions (Fig. 2a–c). In contrast,
there were no significant differences in INO release between
5NTE+/+ and 5NTE−/− cells in control, GD, or OGD conditions
(Fig. 2a–c). In 5NTE+/+ cells, GD and OGD produced greater
increases in INO than ADO levels (Fig. 2b, c).
DPR, which inhibits equilibrative nucleoside transporters 1
and 2, produced a significant increase in ADO in buffer-
treated and OGD-treated 5NTE+/+ astrocytes (Fig. 2a, c). No
effect of DPR on ADO levels was observed in 5NTE−/−
astrocytes (Fig. 2a–c). In contrast, DPR reduced INO levels
in both 5NTE+/+ and 5NTE−/− astrocytes and this inhibition
was evident in buffer-, GD-, and OGD-treatment conditions
(Fig. 2a–c). Similar to DPR, dilazep also inhibited INO levels
in 5NTE+/+ astrocytes (data not shown).
AOPCP was observed to inhibit ADO production in
5NTE+/+ astrocytes in buffer-, GD-, and OGD-treatment con-
ditions (Fig. 2a–c). In contrast, AOPCP had no effect on ADO
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production in 5NTE−/− astrocytes and also had no effect on
INO levels in either cell type (Fig. 2a–c).
In ischemia-like conditions, co-cultures of wild type neurons
with 5NTE+/+ astrocytes produced more ADO but similar
INO compared to co-cultures of wild type neurons
with 5NTE−/− astrocytes
Neuron-astrocyte co-cultures consisting of wild-type neurons
cultured with astrocytes from either 5NTE+/+ or 5NTE−/−mice
were compared to assess ADO and INO release under phys-
iological buffer (control), GD, or OGD conditions. Under
these treatment conditions, co-cultures with eN-competent
cells produced more ADO than co-cultures deficient in eN
(Fig. 3a–c). In contrast, for each treatment condition, INO
production was similar between cell cultures (Fig. 3a–c).
Using co-cultures, ADO formation was not significantly af-
fected by DPR or AOPCP (Fig. 3a–c). In contrast, INO
production was consistently reduced by DPR, but not
AOPCP (Fig. 3a–c).
NMDA-evoked release of ADO and INO was reduced
in astrocyte-neuron co-cultures containing 5NTE−/− astrocytes
relative to co-cultures containing 5NTE+/+astrocytes
Neuron-astrocyte co-cultures consisting of wild-type
neurons cultured with astrocytes from either 5NTE+/+
or 5NTE−/− mice were treated with buffer or NMDA
Fig. 1 Ecto-5′ nucleotidase (eN) assays in cortical tissues and cultured
astrocytes from 5NTE+/+ or 5NTE−/− mice. a Membrane proteins were
extracted from tissue and incubated with 10 μM [14C] AMP, with or
without 50 μM AOPCP for 10 min. Supernatants were collected and
ADO, INO, and HX were separated by TLC then quantified by scintilla-
tion spectroscopy. Data are expressed as means±SEM (n=6). A signifi-
cant effect of AOPCP to inhibit ADO production in Wt tissue was
identified by two-way ANOVA, followed by Bonferroni test for multiple
comparisons. ***P<0.001. b Cultured astrocytes were first treated with
30 μM DPR for 15 min and then treated for 10 min with a reaction
mixture containing final concentrations of 10 μM [14C] AMP and 30 μM
DPR with or without 50 μM AOPCP. Afterwards, supernatant was
collected for TLC and quantified by scintillation spectrometry. Data are
expressed as mean±SEM (n=18). A significant effect of AOPCP to
inhibit ADO production in 5NTE+/+ cells was identified by two-way
ANOVA, followed by Bonferroni test for multiple comparisons.
***P<0.001
Fig. 2 ADO and INO release from 5NTE+/+ or 5NTE−/− astrocyte cul-
tures in energy-depleting conditions. Cells were pre-incubated with [3H]
adenine and then treated with a buffer, b glucose deprivation (GD), or c
oxygen-glucose deprivation (OGD) in the absence or presence of 30 μM
DPR or 50μMAOPCP. For buffer and GD conditions, supernatants were
collected after 30 min. For OGD conditions, supernatants were collected
after 1 h in a humidified chamber containing 95 % N2 and 5 % CO2 at
37 °C. [3H] Purines were separated by TLC and analyzed by scintillation
spectroscopy. Analysis was done by one-way ANOVA with post hoc
analysis using Dunnett’s multiple comparison test. Data are expressed as
means±SEM (n=18–20). ***P<0.001; **P<0.01, *P<0.05 compared
with buffer, GD, or OGD treatments
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and evaluated for ADO and INO release. NMDA treat-
ment increased both ADO and INO production in both
wild-type and eN-deficient co-cultures (Fig. 4a, b). DPR
significantly reduced NMDA-evoked ADO and INO
release from both wild-type and eN-deficient co-cultures
(Fig. 4a, b). In contrast, AOPCP had no significant
effect on either ADO or INO in either co-culture
(Fig. 4a, b).
Discussion
The main findings of this study were that astrocytes cultured
from 5NTE−/− mice produced virtually no ADO in the pres-
ence of buffer or in response to GD or OGD treatment, in
contrast to 5NTE+/+ astrocytes. A similar lack of ADO pro-
duction was observed in co-cultures of wild-type neurons with
5NTE−/− astrocytes treated with these ischemia-like condi-
tions. However, NMDA treatment did evoke ADO production
in co-cultures of wild-type neurons with 5NTE−/− astrocytes.
Regarding INO production from astrocyte cultures or
astrocyte-neuron co-cultures, the deficiency of eN did not
have an effect.
ADO format ion f rom AMP in normoxic and
normoglycemic cortical membrane preparations and cortical
astrocyte cultures was largely dependent upon eN. This was
confirmed by the use of AOPCP to inhibit eN activity in
5NTE+/+ preparations and by the substantially reduced quan-
tities of ADO produced by 5NTE−/− preparations. The residual
ADO present in 5NTE−/− membranes and astrocyte cultures
(Fig. 1) may indicate a small contribution of alternate enzyme
Fig. 3 ADO and INO release from CD1 neuron-5NTE+/+ astrocyte (Wt)
and CD1 neuron-5NTE−/− astrocyte (eN (−)) co-cultures. Co-cultures
were incubated with [3H] adenine then treated with a buffer, b glucose
deprivation (GD), or c oxygen-glucose deprivation (OGD) in the absence
or presence of 30 μM DPR or 50 μM AOPCP. For buffer and GD
conditions, extracellular fluid was collected after 30 min. For OGD
conditions, the supernatants were collected after 1 h in a humidified
chamber containing 95 % N2 and 5 % CO2 at 37 °C. [
3H] Purines were
separated by TLC and analyzed by scintillation spectroscopy. Data are
expressed as means±SEM (n=20–24). Statistical analysis between con-
trol and treatment groups for CD1-5NTE+/+ or CD1-5NTE−/− co-cultures
was performed by one-way ANOVA and post hoc analysis with Tukey’s
tests. ***P<0.001 compared to CD1-5NTE+/+ or CD1-5NTE−/− co-cul-
ture buffer, GD, or OGD treatments
Fig. 4 ADO and INO release from CD1 neuron-5NTE+/+ astrocyte (Wt)
and CD1 neuron-5NTE−/− astrocyte (eN (−)) co-cultures. Co-cultures
were incubated with [3H] adenine then treated with a buffer, 30 μM
DPR, 100 μM NMDA, or DPR+NMDA or b buffer, 50 μM AOPCP,
100 μMNMDA, or AOPCP+NMDA. Supernatants were collected after
30-min incubation at 37 °C. [3H] Purines were separated by TLC and
analyzed by scintillation spectroscopy. Data are expressed as means±
SEM (n≥9). Statistical analysis was performed by one-way ANOVA and
post hoc analysis with Tukey’s tests. ***P<0.001; **P<0.01, *P<0.05
comparedwith buffer-treated CD1-5NTE+/+ or CD1-5NTE−/− co-cultures.
+++P<0.001 compared to NMDA-treated CD1-5NTE+/+ or CD1-5NTE−/−
deficient co-cultures
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activities, such as tissue non-specific alkaline phosphatase, as
reported previously [12]. The eN assay conditions were rela-
tively clear of contamination from enzymes producing INO or
hypoxanthine. The small quantities of these purines produced
in astrocyte cultures (Fig. 1b) may indicate that the concen-
tration of DPR used (30 μM) was not completely effective in
preventing cellular uptake of extracellular ADO or release of
intracellularly formed purines.
Previously, we reported that the greatest amount of ADO
evoked from astrocytes occurred with inhibition of both glycol-
ysis and oxidative phosphorylation for 60min [3]. In the present
study, we inhibited glycolysis by exposing astrocyte cultures to
2DG, a competitive inhibitor of hexokinase, a key enzyme in
glycolysis. We inhibited oxidative phosphorylation by placing
astrocytes in an oxygen-depleted humidified chamber. eN ac-
tivity was important for ADO production in basal, GD, and
OGD conditions. First, extracellular ADO was low, almost
undetectable, in cultures of 5NTE−/− astrocytes. Second,
AOPCP decreased ADO levels in 5NTE+/+ astrocytes. Third,
DPR increased ADO indicating that ADO was formed extra-
cellularly and DPR-sensitive nucleoside transporters mediated
cellular uptake and removal of ADO. Because AOPCP signif-
icantly reduced ADO levels in 5NTE+/+ cells but extracellular
ADO levels in 5NTE−/− cells were insensitive to GD and OGD
treatments, it appears that eN was an important source of
extracellular ADO even under ischemia-like conditions that
inhibit intracellular ATP production.
Astrocyte cultures produced extracellular INO in addition
to ADO. Consistently, in both 5NTE+/+ and 5NTE−/− astrocyte
cultures, INO levels were reduced by DPR but not by AOPCP,
indicating that INO is produced intracellularly and released
via nucleoside transporters under basal and ischemia-like
conditions. Dilazep, an ENT1 and ENT2 inhibitor structurally
unrelated to DPR, also inhibited extracellular INO levels in
5NTE+/+ astrocyte cultures. As ADO levels were increased,
but INO levels were decreased byDPR, we conclude that INO
was produced by an intracellular pathway in contrast to the
extracellular pathway for ADO formation. Further, both the
presence of AOPCP and the absence of eN inhibited ADO but
had no effect on INO. Thus, INO was not produced simply as
a downstream metabolite of ADO in astrocyte cultures.
Using astrocyte-neuron co-cultures, more ADO was pro-
duced in cultures containing 5NTE+/+ astrocytes than in cul-
tures containing 5NTE−/− astrocytes. ADO production was
virtually undetectable in co-cultures that contained 5NTE−/−
astrocytes. In contrast, INO production was similar between
the two co-cultures. As in astrocyte cultures, INO was signif-
icantly reduced by DPR, indicating an intracellular source of
this purine. In contrast to 5NTE+/+ astrocyte cultures, ADO
was not significantly affected by AOPCP or DPR in 5NTE+/+
astrocyte-neuron co-cultures in control or ischemia-like con-
ditions. Thus, neurons appear to contribute additional path-
ways for ADO production and removal that counteract the
contributions of astrocytic eN and DPR-sensitive nucleoside
transporters.
In previous studies, we treated hippocampal slices with
hypoxia or OGD and found that ADO A1 receptor activity, a
measure of extracellular ADO levels, was reduced by overex-
pression of ENT1, a DPR-sensitive nucleoside transporter,
indicating an extracellular site of ADO production [11].
However, the hypoxia or OGD-induced increases in ADO
A1 receptor activity were not affected by the absence of eN,
indicating either another extracellular enzyme, such as tissue
non-specific alkaline phosphatase, or another release mecha-
nism for ADO [12]. The present study also indicates a role for
additional sources of ADO in astrocyte-neuron co-cultures
treated with GD or OGD.
In experiments using biosensors to detect ATP and ADO,
OGD was found to increase extracellular levels of both of
these purines in hippocampal slices [14]. While nucleoside
transport inhibitors increased ADO levels, indicating extracel-
lular formation of ADO, the ATP and ADO increases ap-
peared to result from independent mechanisms; thus, it was
concluded that ADO was not simply a metabolite of ATP
release [14]. Although the role of eN was not addressed
directly, as ADO production was not correlated to ATP levels,
it may have also been independent of eN activity. With respect
to INO formation, biosensors were used to compare ADO and
INO formation in hippocampal slices [15]. Hypoxia increased
both nucleosides but had a greater effect on ADO than INO, in
contrast to the cell culture data reported here.
Fast-scan cyclic voltammetry has been used to measure
adenosine levels in brain slices and in vivo brain cortex [16,
17]. Mechanical or brief electrical stimulations increased ADO
levels; partial reductions in ADO levels were achieved with
ARL 65156 and AOPCP or POM-1, drugs that inhibit extracel-
lular metabolism of adenine nucleotides. Using these stimula-
tion conditions, there was no evidence for release of cytoplas-
mic ADO as nucleoside transport inhibitors had no effect.
In contrast to GD and OGD, exposure of astrocyte-neuron
co-cultures to NMDA, an agonist for the NMDA subtype of
glutamate receptors, stimulated significant increases in extra-
cellular levels of both ADO and INO in co-cultures containing
either 5NTE+/+ or 5NTE−/− astrocytes. For both ADO and
INO, DPR, but not AOPCP, significantly reduced NMDA-
induced increases. These data indicate that NMDA treatment
produces both ADO and INO that are formed intracellularly
and released via nucleoside transporters. Previous studies
have shown that NMDA has little effect on ADO production
in astrocyte cultures, despite reports that astrocyte cultures
express functional NMDA receptors [18, 19]. Therefore, our
results indicate that NMDA selectively activates neurons and
stimulates cytosolic formation of ADO and INO, which are
subsequently effluxed via membrane transporters.
A previous study, which used rat cortical astrocytes and rat
cortical neurons in co-culture, reported that NMDA
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significantly increased INO but did not significantly increase
ADO production [20]. In these rat co-cultures, AOPCP, but
not DPR, inhibited ADO production. The difference between
these earlier results and the present findings could be species
of origin of the cells, or the number of astrocytes used to
initiate the co-cultures. In the earlier study, astrocytes were
confluent prior to the addition of neurons [20] whereas in the
present study, astrocytes were sub-confluent, and this may
have reduced the contribution of eN to ADO formation and
reduced the inhibitory effect of AOPCP in the present study.
Brain ischemia arises from brain trauma, stroke, or cardiac
arrest. Extensive research has focused on neurons as these cells
are particularly sensitive to ischemic insult [21]. Astrocytes are
less sensitive to ischemic damage than neurons [21, 22], in part,
because as non-excitable cells, astrocytes have a reduced rate of
ATP consumption than neurons. Further, these cells contain
glycogen, which allows ATP synthesis to continue to a limited
extent during ischemia. Previously, we reported the enhanced
rate of ATP depletion in neurons compared to astrocytes in
ischemia-like conditions [3]. These differences in rates of ATP
depletion may, in part, explain the intracellular formation of
ADO by neurons but not by astrocytes.
In summary, this study shows that eN activity by astrocytes
produces ADO under basal conditions and in response to GD
and OGD. It has a reduced role in ADO formation in astrocyte-
neuron co-cultures and does not contribute to ADO produced in
response to NMDA treatment of astrocyte-neuron co-cultures.
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